ArsciMed Market Summary

Key Factors Driving ArsciMed Growth

1. Positive Phase II efficacy in chronic GvHD supports advancement toward pivotal development

Arscimed has demonstrated encouraging efficacy and safety in a Phase II study in chronic GvHD, a disease with limited effective treatment options following allogeneic hematopoietic stem cell transplantation. According to BioSenic/Medsenic, the study showed clinically meaningful responses with a favorable safety profile, supporting progression toward an international confirmatory Phase III program. Positive mid-stage data substantially improve the asset's commercial potential if future pivotal trials are successful.

2. Orphan Drug Designation provides regulatory and commercial advantages

Arscimed has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA) for graft-versus-host disease. These designations provide important incentives including protocol assistance, reduced regulatory fees, and the potential for market exclusivity following approval. Such incentives are particularly valuable in rare diseases where premium pricing and rapid adoption are achievable.

3. Differentiated immunomodulatory mechanism expands opportunities beyond GvHD

Unlike the cytotoxic use of arsenic trioxide in acute promyelocytic leukemia, Arscimed is being developed for its immunomodulatory effects, including regulation of activated T cells and inflammatory pathways. Based on preclinical and clinical findings, Medsenic is expanding development toward systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) using its arsenic trioxide platform, significantly increasing the long-term addressable market if clinical efficacy is confirmed.

4. Pharmaceutical equivalence with Trisenox may facilitate clinical development

Clinical trial documentation states that Arscimed and Trisenox® contain the same active ingredient (arsenic trioxide), dosage form, excipients, and route of administration, and are considered therapeutically equivalent for the purposes of ongoing clinical studies. Development of Arscimed was intended to ensure reliable product supply after previous Trisenox shortages affected patient recruitment, reducing manufacturing-related development risk.

5. Proprietary manufacturing and lifecycle management strengthen long-term value

BioSenic has developed proprietary manufacturing know-how for Arscimed and is simultaneously advancing next-generation oral arsenic trioxide formulations (OATO) to improve convenience and expand indications. The company has stated that the intravenous formulation is protected through proprietary manufacturing expertise while oral formulations are being developed for broader autoimmune applications, creating opportunities for lifecycle management and portfolio expansion.

ArsciMed Recent Developments

In July 2024, BIOSENIC announced the signature of global licensing, supply and commercialization agreements with Phebra Pty Ltd. related to the adaptation of the License Agreement and the MDA signed earlier in May 2021, when Phebra became a minority shareholder in Medsenic SAS. The improved terms will make it more attractive for investors to participate in the financing of the upcoming Phase 3 trial of oral arsenic trioxide (OATO/ ArsciCor). This new licensing agreements between Medsenic SAS and Phebra Pty Ltd should facilitate the final steps of manufacturing, clinical confirmation of efficacy and subsequent commercialization of our oral arsenic drug in the field of chronic Graft versus Host Disease (cGvHD).

“ArsciMed Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ArsciMed for potential indication like Graft-versus-host disease; Systemic lupus erythematosus, Encephalomyelitis, Multiple sclerosis, and Systemic scleroderma in the 7MM. A detailed picture of ArsciMed’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ArsciMed for potential indications. The ArsciMed market report provides insights about ArsciMed’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ArsciMed performance, future market assessments inclusive of the ArsciMed market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ArsciMed sales forecasts, along with factors driving its market.

ArsciMed Drug Summary

ArsciMed (Arsenic trioxide) is an investigational intravenous formulation of arsenic trioxide developed by Medsenic for the prevention and treatment of immune-mediated disorders, with a primary focus on acute graft-versus-host disease (aGVHD). ARSCIMED contains the same active ingredient, concentration, dosage form, and route of administration as the marketed arsenic trioxide product TRISENOX®, and has been evaluated as an equivalent formulation in clinical studies. Its therapeutic rationale is based on the immunomodulatory properties of low-dose arsenic trioxide, which selectively induces apoptosis of activated alloreactive T cells, promotes expansion of regulatory T cells (Tregs), and restores immune tolerance while limiting tissue inflammation. ARSCIMED is administered by intravenous infusion and has been investigated in combination with standard immunosuppressive regimens in patients undergoing allogeneic hematopoietic stem cell transplantation. Clinical studies have demonstrated encouraging safety, tolerability, and potential efficacy in reducing the incidence and severity of aGVHD, supporting its continued clinical development as a targeted immunomodulatory therapy for transplantation-related complications. The report provides ArsciMed’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ArsciMed Market Report

The report provides insights into:

• A comprehensive product overview including the ArsciMed MoA, description, dosage and administration, research and development activities in potential indication like Graft-versus-host disease; Systemic lupus erythematosus, Encephalomyelitis, Multiple sclerosis, and Systemic scleroderma.
• Elaborated details on ArsciMed regulatory milestones and other development activities have been provided in ArsciMed market report.
• The report also highlights ArsciMed‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ArsciMed market report also covers the patents information, generic entry and impact on cost cut.
• The ArsciMed market report contains current and forecasted ArsciMed sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ArsciMed market report also features the SWOT analysis with analyst views for ArsciMed in potential indications.

Methodology

The ArsciMed market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ArsciMed Analytical Perspective by DelveInsight

• In-depth ArsciMed Market Assessment

This ArsciMed sales market forecast report provides a detailed market assessment of ArsciMed for potential indication like Graft-versus-host disease; Systemic lupus erythematosus, Encephalomyelitis, Multiple sclerosis, and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ArsciMed sales data uptil 2034.

• ArsciMed Clinical Assessment

The ArsciMed market report provides the clinical trials information of ArsciMed for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ArsciMed Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ArsciMed Market Potential & Revenue Forecast

• Projected market size for the ArsciMed and its key indications
• Estimated ArsciMed sales potential (ArsciMed peak sales forecasts)
• ArsciMed Pricing strategies and reimbursement landscape

ArsciMed Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ArsciMed Market positioning compared to existing treatments
• ArsciMed Strengths & weaknesses relative to competitors

ArsciMed Regulatory & Commercial Milestones

• ArsciMed Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ArsciMed Clinical Differentiation

• ArsciMed Efficacy & safety advantages over existing drugs
• ArsciMed Unique selling points

ArsciMed Market Report Highlights

• In the coming years, the ArsciMed market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ArsciMed companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ArsciMed’s dominance.
• Other emerging products for Graft-versus-host disease; Systemic lupus erythematosus, Encephalomyelitis, Multiple sclerosis, and Systemic scleroderma are expected to give tough market competition to ArsciMed and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ArsciMed in potential indications.
• Analyse ArsciMed cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ArsciMed sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ArsciMed in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ArsciMed? How strong is ArsciMed’s clinical and commercial performance?
• What is ArsciMed’s clinical trial status in each individual indications such as Graft-versus-host disease; Systemic lupus erythematosus, Encephalomyelitis, Multiple sclerosis, and Systemic scleroderma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ArsciMed Manufacturers?
• What are the key designations that have been granted to ArsciMed for potential indications? How are they going to impact ArsciMed’s penetration in various geographies?
• What is the current and forecasted ArsciMed market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ArsciMed in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ArsciMed for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ArsciMed? What is the duration of therapy and what are the geographical variations in cost per patient?